Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
AssigneeTiziana Life Sciences PLC
InventorKunwar SHAILUBHAI
Life of this patent
Estimating the term…
Abstract
The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.
Claims25
A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
- PLA-mPEG, wherein the nanoparticles have an average size of about 100 nm to about 200 nm.
-8. (canceled)
A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
- PLGA-mPEG, wherein the nanoparticles have an average size of about 100 nm to about 200 nm.
(canceled)
-20. (canceled)
A composition comprising a therapeutically effective amount of dactinomycin encapsulated in nanoparticles comprising
- poly(lactic acid) (PLA), wherein the nanoparticles have an average size of about 100 nm to about 200 nm.
-37. (canceled)
-51. (canceled)
Dependencies are inferred from the claim text.